Emirates program supports UAE rugby players

Marwa Abdel Aziz Al-Naqbi represents the second tier of UAE’s female Emirati player. She plays with UAE Rugby’s all-Emirati “Al Maha” U19 girls team.
Updated 30 September 2019

Emirates program supports UAE rugby players

Emirates has presented two Emirati rugby youth players with the opportunity of a lifetime to lead out the teams competing in the bronze final on Nov. 1 in Tokyo Stadium during Rugby World Cup 2019. The initiative is part of the airline’s international flagbearer’s program, which provides opportunities for young fans to lead out teams to the pitch and participate in the pre-kick-off anthem ceremonies across key matches in the quarter-finals, semifinals, the bronze final and the final throughout 12 host cities in Japan.

Saoud Al-Kaabi and Marwa Abdel Aziz Al-Naqbi were unanimously selected by the UAE Rugby Federation board for their exemplary performance and commitment to the game of rugby. Al-Kaabi is currently the only Emirati of his age-group who plays in the “U16 Al-Ain Amblers,” an expatriate domestic-league team.

Al-Naqbi, 15, represents the second tier of UAE’s female Emirati players. She plays with UAE Rugby’s all-Emirati “Al Maha” U19 girls team.

Boutros Boutros, divisional senior vice president corporate communications, marketing & brand, said: “Emirates is committed to growing the game of rugby through grassroots support of local organizations, teams, events and players, ensuring the sport has a strong presence across all communities here in the UAE. We have been a longstanding partner through our support of the UAE Rugby Federation, and will continue to work with them to boost the ongoing development of the game.”


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.